Group 1 - AstraZeneca disclosed multiple lawsuits related to personal information infringement and illegal trade in its 2025 annual report [1] - In October 2025, AstraZeneca (China) received a final assessment from Shenzhen Customs indicating unpaid import taxes totaling 24 million RMB (approximately 3.5 million USD) related to specific drugs [1] - AstraZeneca (China) prepaid the compensation amount in full, but could face fines of 1 to 5 times the unpaid import tax if found liable for illegal trade [1] Group 2 - In November 2025, the Shenzhen People's Procuratorate completed its assessment, leading to public prosecution of AstraZeneca (China), a former executive vice president, and a former senior employee for illegal collection of personal information and illegal trade [1] - The former executive vice president and senior employee were additionally charged with medical insurance fraud, although AstraZeneca (China) was not prosecuted for this charge [1] - The mentioned cases have been consolidated into a single litigation process at the Shenzhen Intermediate People's Court, with no trial date scheduled yet [1]

Core Insights - AstraZeneca has faced multiple allegations in China, including personal information infringement, illegal trade, and medical insurance fraud, as disclosed in its 2025 annual report [1][2] - The company has voluntarily prepaid a compensation amount of RMB 24 million (approximately USD 3.5 million) related to unpaid import taxes for specific drugs [1] - AstraZeneca's revenue in China for 2025 was USD 6.654 billion, representing a 4% year-on-year growth, contributing approximately 11% to the company's total revenue of USD 58.739 billion, which grew by 8% [4][5] Legal Developments - In October 2025, Shenzhen Customs issued a final assessment indicating AstraZeneca China owed RMB 24 million in import taxes, with potential penalties of one to five times the paid amount if found liable for illegal trade [1] - In November 2025, the Shenzhen Prosecutor's Office completed its assessment, leading to charges against AstraZeneca China and its former executives for illegal collection of personal information and illegal trade, although AstraZeneca China was not accused of profiting from the illegal activities [1][2] Management Changes - Following the investigation, AstraZeneca appointed Iskra Reic as the new Global Executive Vice President and head of International Business, while Lin Xiao became the General Manager of AstraZeneca China [3] Investment Plans - AstraZeneca announced a USD 2.5 billion investment plan in March 2025 to establish a global strategic R&D center in Beijing, alongside collaborations with several biotech companies [4] - The company plans to invest over RMB 100 billion (approximately USD 15 billion) in China by 2030 to expand its drug production and R&D capabilities, which is expected to create thousands of new jobs [5]